Thoracic Cancer (Feb 2024)

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

  • Ayu Kiritani,
  • Yoshiaki Amino,
  • Ken Uchibori,
  • Takahiro Akita,
  • Yuhei Harutani,
  • Shinsuke Ogusu,
  • Ryosuke Tsugitomi,
  • Ryo Manabe,
  • Ryo Ariyasu,
  • Satoru Kitazono,
  • Noriko Yanagitani,
  • Makoto Nishio

DOI
https://doi.org/10.1111/1759-7714.15210
Journal volume & issue
Vol. 15, no. 5
pp. 402 – 409

Abstract

Read online

Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertinib for malignant pleural effusion (MPE) remains understudied. This study aimed to evaluate the impact of osimertinib on time to treatment failure (TTF) and overall survival (OS) in patients with EGFR‐mutation positive NSCLC, comparing those with and without MPE. Methods This retrospective analysis included patients with advanced or recurrent NSCLC treated with osimertinib at our hospital between April 2016 and June 2021. TTF was defined as the duration from osimertinib initiation to discontinuation, and OS as the duration until death, irrespective of the reason. Results Among 229 patients receiving osimertinib, 84 had MPE before administration, 39 acquired EGFR exon20 T790M mutation following previous EGFR‐TKI therapy, and 45 were EGFR‐TKI‐naive. Among EGFR‐TKI‐naive patients, median TTF was 14.8 and 19.8 months for those with and without MPE, respectively (hazard ratio [HR] 1.40; 95% confidence interval [CI]: 0.90–2.18; p = 0.12). Median OS was 32.0 and 42.0 months for patients with and without MPE, respectively (HR 1.43; 95% CI: 0.86–2.38; p = 0.16). Among patients with T790M mutation, median TTF was 12.3 and 13.1 months for patients with and without MPE, respectively (HR 1.03; 95% CI: 0.69–1.55; p = 0.88). Median OS for patients with and without MPE was 23.2 and 24.7 months, respectively (HR 1.09; 95% CI: 0.72–1.67; p = 0.68). Conclusion Among patients with EGFR‐mutation positive NSCLC, the evidence of MPE has little effect on survival with osimertinib.

Keywords